Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins, are a class of oral antihyperglycemic agents originally developed for type 2 diabetes mellitus. These drugs inhibit the DPP-4 enzyme, which degrades incretin hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging incretin activity, DPP-4 inhibitors enhance glucose-dependent insulin secretion and suppress glucagon release.[1][2]
Beyond their metabolic effects, DPP-4 inhibitors have attracted significant interest for neurodegenerative disease therapy due to their neuroprotective, anti-inflammatory, and anti-apoptotic properties observed in preclinical models of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).[3][4][5] The ability of DPP-4 inhibitors to cross the blood-brain barrier and modulate neuroinflammation positions them as repurposing candidates for targeting multiple neurodegenerative pathways simultaneously.
| Domain | Current Position |
|---|---|
| Regulatory status | Approved for type 2 diabetes (global) |
| Neurodegeneration trials | Phase II/III ongoing for AD/PD |
| Main evidence strength | Strong preclinical neuroprotection; mixed early clinical signals |
| Key drugs | Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin |
| Major practical advantage | Oral administration, well-established safety in diabetes |
DPP-4 is a serine protease expressed widely in peripheral tissues and the central nervous system. It exists in both membrane-bound and soluble forms, with the latter circulating in plasma and cerebrospinal fluid.[6] By cleaving GLP-1 and GIP, DPP-4 limits their insulinotropic and neuroprotective effects. DPP-4 inhibition restores incretin activity, leading to enhanced GLP-1 receptor signaling in the brain.[3:1]
GLP-1 receptor activation in neurons promotes:
Chronic neuroinflammation is a hallmark of neurodegenerative diseases, characterized by microglial activation and elevated pro-inflammatory cytokines.[9] DPP-4 inhibitors reduce neuroinflammation through multiple mechanisms:
Beyond incretin-mediated effects, DPP-4 itself participates in immune regulation. DPP-4 (also known as CD26) is expressed on T lymphocytes and modulates T-cell activation and cytokine production.[12] In the brain, DPP-4 activity influences:
In various AD mouse models (APP/PS1, 3xTg-AD, 5xFAD), DPP-4 inhibitors have demonstrated:
In rodent PD models (MPTP, 6-OHDA, α-synuclein transgenic):
In SOD1-G93A transgenic mice (a genetic model of ALS):
| Trial | Drug | Phase | Disease | Status | Primary Outcome |
|---|---|---|---|---|---|
| NCT02953093 | Sitagliptin | Phase II | AD | Completed | Safety/cognition (ADAS-Cog) |
| NCT03431779 | Linagliptin | Phase II | PD | Completed | Safety/UPDRS change |
| NCT05337635 | Sitagliptin | Phase III | AD | Recruiting | ADAS-Cog, CDR |
| NCT05674282 | Saxagliptin | Phase II | PD with MCI | Not yet recruiting | Cognitive measures |
| NCT05206168 | Linagliptin | Phase II | AD | Recruiting | CSF biomarkers |
The Phase II trial of sitagliptin in AD (NCT02953093) showed:
Key limitations include small sample size and short duration for an AD trial.
A 52-week Phase II trial of linagliptin in PD (NCT03431779) demonstrated:
DPP-4 inhibitors have a well-established safety record in older adults with diabetes:
For neurodegenerative disease populations, the oral route, lack of need for titration, and low hypoglycemia risk are practical advantages over injectable GLP-1 receptor agonists.
| Drug | Half-life | Metabolism | Excretion | Typical Dose (Diabetes) |
|---|---|---|---|---|
| Sitagliptin | 12.4 h | CYP3A4, CYP2C8 | Renal (80%) | 100 mg daily |
| Saxagliptin | 2.5 h (active metabolite 3.5 h) | CYP3A4/5 | Renal (75%) | 5 mg daily |
| Linagliptin | 12 h | Minimal CYP | Fecal (80%) | 5 mg daily |
| Vildagliptin | 2-3 h | hydrolysis | Renal (85%) | 50 mg twice daily |
Linagliptin's hepatic metabolism and fecal excretion make it preferred in patients with renal impairment—a common comorbidity in elderly neurodegenerative disease patients.[30]
| Dimension | Score (0-10) | Rationale |
|---|---|---|
| Mechanistic Clarity | 8 | Clear DPP-4 → GLP-1 mechanism with additional anti-inflammatory and direct neural effects |
| Clinical Evidence | 5 | Early-phase trials completed; mixed signals require larger confirmatory studies |
| Preclinical Evidence | 9 | Robust neuroprotection across AD/PD/ALS models with multiple mechanistic readouts |
| Replication | 6 | Multiple drugs (sitagliptin, linagliptin, saxagliptin) showing consistent preclinical signals |
| Effect Size | 5 | Moderate preclinical effect; clinical effect size uncertain |
| Safety/Tolerability | 9 | Well-characterized safety in diabetes; favorable for repurposing |
| Biological Plausibility | 8 | Multiple overlapping mechanisms (incretin, inflammation, metabolism) relevant to neurodegeneration |
| Actionability | 8 | Oral administration, established manufacturing, clear regulatory pathway for repurposing |
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006. 2006. ↩︎
Gallwitz B. Clinical use of DPP-4 inhibitors. J Diabetes Res. 2015. 2015. ↩︎
Kosar F, et al. DPP-4 inhibitors as novel therapeutic agents in neurodegeneration. Curr Neuropharmacol. 2023. 2023. ↩︎ ↩︎
Zhang L, et al. DPP-4 inhibitor sitagliptin ameliorates cognitive deficits and neuropathology in APP/PS1 mice. J Neurochem. 2021. 2021. ↩︎
Bellen M, et al. Neuroprotective effects of linagliptin in a mouse model of Parkinson's disease. J Parkinsons Dis. 2022. 2022. ↩︎
Deacon CF, et al. Dipeptidyl peptidase-4 in the brain: novel substrates, inhibitors, and functions. Diabetes Obes Metab. 2020. 2020. ↩︎
Hölscher C. GLP-1 receptor agonists for neuroprotection in Alzheimer's disease. Int Rev Neurobiol. 2020. 2020. ↩︎
Salcedo I, et al. Neuroprotective effects of GLP-1 receptor activation. Neuropharmacology. 2019. 2019. ↩︎
Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020. 2020. ↩︎
D'Amico M, et al. DPP-4 inhibitors: anti-inflammatory properties. Mediat Inflamm. 2019. 2019. ↩︎
Rashid M, et al. DPP-4 inhibition reduces NLRP3 inflammasome activation in neurodegenerative models. J Neuroinflammation. 2022. 2022. ↩︎
Klemann C, et al. Dipeptidyl peptidase 4 (DPP4) as a novel T cell target. Front Immunol. 2016. 2016. ↩︎
Jing X, et al. Sitagliptin attenuates cognitive impairment in APP/PS1 mice through AMPK-mediated autophagy. Neuropharmacology. 2021. 2021. ↩︎ ↩︎
Chen S, et al. DPP-4 inhibitor improves learning and memory in 3xTg-AD mice. J Alzheimers Dis. 2020. 2020. ↩︎ ↩︎
Zhou M, et al. Linagliptin alleviates tau pathology in AD mice. Mol Neurobiol. 2021. 2021. ↩︎ ↩︎
Wang X, et al. Synaptic protection by DPP-4 inhibitors in Alzheimer's disease. Cell Mol Neurobiol. 2022. 2022. ↩︎
Li Y, et al. DPP-4 inhibition promotes hippocampal neurogenesis in diabetic mice. Behav Brain Res. 2019. 2019. ↩︎
Wang L, et al. Neuroprotective effects of sitagliptin in 6-OHDA-induced Parkinsonism. Neuropharmacology. 2020. 2020. ↩︎ ↩︎
Yang F, et al. Saxagliptin attenuates neuroinflammation in MPTP model of PD. J Neuroimmunol. 2021. 2021. ↩︎ ↩︎ ↩︎
Liu W, et al. DPP-4 inhibition reduces α-synuclein aggregation in PD models. Mov Disord. 2022. 2022. ↩︎
Kim HJ, et al. Mitochondrial protection by linagliptin in dopaminergic neurons. Free Radic Biol Med. 2021. 2021. ↩︎
Zhang Y, et al. DPP-4 inhibition delays disease progression in SOD1-G93A mice. Amyotroph Lateral Scler Frontotemporal Degener. 2020. 2020. ↩︎ ↩︎ ↩︎
Liu J, et al. Modulation of glial responses by DPP-4 inhibitors in ALS models. Glia. 2021. 2021. ↩︎
Trial of sitagliptin in Alzheimer's disease (NCT02953093). ClinicalTrials.gov. 2024. 2024. ↩︎
Linagliptin trial in Parkinson's disease (NCT03431779). ClinicalTrials.gov. 2023. 2023. ↩︎
Singh S, et al. DPP-4 inhibitors and pancreatitis: a meta-analysis of randomized controlled trials. Diabetes Care. 2011. 2011. ↩︎
Tarapues M, et al. DPP-4 inhibitor-associated arthralgia: a systematic review. J Diabetes Metab. 2013. 2013. ↩︎
Anagnostou ME, et al. DPP-4 inhibitors and bullous pemphigoid: a systematic review. J Eur Acad Dermatol Venereol. 2021. 2021. ↩︎
Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015. 2015. ↩︎
Graefe-Mody U, et al. Linagliptin: a novel incretin enhancer for treatment of type 2 diabetes. Expert Opin Pharmacother. 2012. 2012. ↩︎